<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04488432</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC19.0137</org_study_id>
    <nct_id>NCT04488432</nct_id>
  </id_info>
  <brief_title>Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant</brief_title>
  <acronym>ENDOCALLOGREFF</acronym>
  <official_title>Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic hematopoietic stem cell transplantations (allo-HSCT) is often indicated in
      malignant hematologic diseases. Conditioning regimens, used to reduce the tumor burden and to
      prevent transplant rejection, are based on chemotherapy alone or combined with total body
      irradiation (TBI). Endocrine complications are frequent transplant-related side effects. They
      have been well described in children studies but less in adulthood.

      Our objective is to assess retrospectively endocrine, bone and metabolic disorders in adult
      patients, 12 months after allo-HSCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients &amp; Methods Inclusion criteria are : patients treated with allo-HSCT from 2006 to 2016
      for a malignant hematologic disease; adult and in complete remission at exploration.

      Exclusion criteria are : anteriority of brain radiotherapy and prior HSCT.

      Twelve months after HSCT, each patient underwent fasting measurement of IGF1, TSH, fT4, FSH,
      LH, sex steroids, glycemia, insulin level, and lipid profile. Unless contraindication,
      adrenal and growth hormone functions were assessed with insulin hypoglycemia test. A dual
      X-ray absorptiometry was also performed.

      We will assess the prevalence of endocrine, bone and metabolic disorders 12 months after
      allo-HSCT and describe some of their risk factors.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adrenal insuffisiency prevalence</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>insulin hypoglycemia test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypothyroidism prevalence</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>fT4, TSH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth hormon Deficiency prevalence</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>insulin hypoglycemia test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premature ovarian failure prevalence</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>FSH, LH, estradiol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of elevated FSH in men</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>FSH, testosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of low bone mineral density</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>dual X-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of obesity</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of dyslipidemia</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of hyperglycemia and insulin-resistance</measure>
    <time_frame>12 month post-alloHSCT</time_frame>
    <description>glycemia and HOMA2-IR index</description>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Endocrine System Diseases</condition>
  <condition>Osteoporosis</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Adrenal Insufficiency</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with allo-HSCT after puberty from 2006 to 2016 in our University Hospital
        of Brest, adult at the endocrine exploration.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients treated with allo-HSCT from 2006 to 2016 for a malignant hematologic disease

          -  adult and in complete remission at exploration.

        Exclusion Criteria:

          -  anteriority of brain radiotherapy

          -  prior HSCT

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>CHRU de Brest - Endocrinology and Diabetology Department</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Adrenal Insufficiency</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

